Evaluating only Pact Pharma’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. That’s exactly how it died.
Key Events Timeline
FOUNDING
Pact Pharma founded to develop personalized neoantigen T-cell receptor therapies for solid tumors.
FUNDING
$100M Series B raised, Roche Ventures leads, valuing company at $400M on promise of individualized cancer immunotherapy.
PRODUCT LAUNCH
Phase 1 data for PP-001 released; modest tumor response rates and 12-16 week vein-to-vein manufacturing time disappoint investors.
SHUTDOWN
Series C financing collapses; Pact Pharma shuts down, lays off 120 staff, and discontinues all clinical programs.
Full Analysis
Free · no account needed
Documented cause
Pact Pharma, a personalized neoantigen T-cell therapy company backed by $145M from investors including Roche Ventures, collapsed in January 2024 after its lead program PP-001 produced disappointing Phase 1 results in solid tumors. The manufacturing process for patient-specific T-cells took 12-16 weeks and cost over $500K per patient, making commercialization economically unviable. CEO Julianne Bhatt announced shutdown after Series C talks broke down in Q4 2023.
Lesson
“Manufacturing scalability and cost-per-patient must be solved before Phase 1 completion, not after.”